Altitude sickness in climbers and efficacy of NSAIDs trial (ASCENT): Randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness
| Autor: | Neda Nicole Farzan, Aaron Michael Stutz, Baotran Vo, Christopher Macguire, Pradip Chapagain, Jeremy Farrar, Charles Hessel Abramson, Jeffrey H. Gertsch, Charles Peter Aloysius Vaughan, Jessica Elizabeth Holly, Matiram Pun, Hillary R. Irons, Amanda Morgan Casto, Nathan Thomas Stillwagon, Allison Mulcahy, Buddha Basnyat, Bryan Corbett, Rebecca Jean Norvelle, Siddhartha Yadav, Peter S. Holck, Melanie Watts, Kerstin May |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
business.industry Incidence (epidemiology) Public Health Environmental and Occupational Health Effects of high altitude on humans Placebo Ibuprofen medicine.disease law.invention Randomized controlled trial law Severity of illness Emergency Medicine Physical therapy medicine Lost to follow-up business Altitude sickness medicine.drug |
| DOI: | 10.1016/j.wem.2012.08.001 |
| Popis: | Objective: To study the effectiveness of ibuprofen versus placebo in preventing acute mountain sickness (AMS) and high altitude headache (HAH). Methods: Double-blind, randomized, placebo-controlled trial. Results: Two hundred ninety-four healthy Western trekkers were recruited on the Everest approach at 4280 m or 4358 m and randomly assigned to receive either 600 mg of ibuprofen or placebo 3 times daily before and during ascent to 4928 m. One hundred eighty-three of 294 participants completed the trial. Of the participants who did not complete the trial, 62 were lost to follow-up and another 49 broke trial protocol. In an intent-to-treat analysis (232 participants), ibuprofen was found to be more effective than placebo in reducing the incidence of AMS (24.4% vs 40.4%; P =.01) and the incidence of HAH (42.3% vs 60.5%; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|